Cambridge Heart adds $12.5M in marketing deal with St. Jude

Young, Karen
March 2007
Medical Device Daily;3/23/2007, Vol. 11 Issue 56, p2
The article reports on the new three-year sales and marketing agreement of Cambridge Heart with Saint Jude Medical. Under the agreement, Saint Jude will be marketing Cambridge Heart's HearTwave II Microvolt T-Wave Alternans System and sensors to cardiologists and electrophysiologists in North America. Saint Jude has purchased $12.5 million in preferred stock in Cambridge Heart which are convertible into common stock at $2.99 per share.


Related Articles

  • Cambridge Heart tweaks pact with St. Jude for HearTwave II MTWA.  // Cardiovascular Device Update;Jul2007, Vol. 13 Issue 7, p18 

    The article reports on the amendment of the sales and marketing agreement between Cambridge Heart and Saint Jude Medical in relation to the HearTwave II Microvolt T-Wave Alternans (MTWA) test from Cambridge Heart. Under the agreement, Saint Jude Medical can market the MTWA test to North American...

  • ACC notebook.  // Medical Device Daily;3/16/2010, Vol. 14 Issue 50, p4 

    The article reports on the PressureWire platform of St. Jude Medical, which includes a new marketing agreement with Siemens Medical Solutions.

  • St. Jude, Zonare combine in intracardiac imaging.  // Medical Device Daily;11/17/2010, Vol. 14 Issue 224, p3 

    The article reports on the development and marketing agreement between St. Jude Medical and Zonare Medical Systems.

  • St. Jude Medical. Investor's Business Daily // Investors Business Daily;1/23/2014, pA02 

    St. Jude Medical ([STOCK[STJ]]) reported a 7.6% jump in Q4 EPS to 99 cents, beating views by 2 cents. Sales rose 3.8% to $1.42 bil, above views for $1.38 bil on increased sales of defibrillators and atrial fibrillation devices. The medical device company expects Q1 EPS of 94-96 cents, the...

  • St. Jude Medical Announces 2nd Qtr Dividend.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article informs that Saint Jude Medical Inc. has released its 2nd quarter dividend which has been accounted to be 0.23 dollar per common share.

  • St. Jude Medical Announces Increase in Quarterly Dividend.  // Biomedical Market Newsletter;2/28/2012, Vol. 21, p1 

    The article informs that Saint Jude Medical Inc. has announced a 10 percent increase in its quarterly dividend which is payable on March 30, 2012 for shareholders of record. It mentions that the annual dividend will account to 0.92 dollar per share. It further informs that Saint Jude Medical is...

  • Financings Roundup.  // BioWorld Today;4/19/2011, Vol. 22 Issue 75, p5 

    The article reports that Cytokinetics Inc. is expecting a 20.1 million U.S. dollar gross from the sale of its 5.3 million shares of common stock and 8,070 shares of Series A convertible preferred stock.

  • Financings Roundup.  // BioWorld Today;2/10/2012, Vol. 23 Issue 19, p6 

    The article reports on the plan of Tarrytown, New York-based EpiCept Corp. to raise about 1.8 million U.S. dollars by offering 2,000 shares of its Series A 0 percent convertible preferred stock at 1,000 U.S. dollars per share to an institutional investor.

  • Cambridge Heart completes Series D placement, gains $1.8M.  // Medical Device Daily;12/29/2009, Vol. 13 Issue 249, p2 

    The article reports on the completion of a private placement of Series D convertible preferred stock by Cambridge Heart in 2009. The company was able to secure nearly 1.8 million U.S. dollar from the Series D financing. Such Series D financing included convertible preferred stock, shares of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics